BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• Business

  Labcorp to Announce Second Quarter Financial Results on August 1, 2024

  Labcorp will release its financial results for the second quarter of 2024 before the market opens on Thursday, August 1, 2024.

  July 1, 2024

   · 

  1 min read
• Drug Development

  Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327

  Recce Pharmaceuticals Ltd today announced positive data from a Phase I/II trial for urinary tract infections (UTIs) and urosepsis, demonstrating that its lead candidate, RECCE® 327 (R327), administered intravenously is safe and efficacious against Escherichia coli (E. coli).

  July 1, 2024

   · 

  5 min read
• Pharm Country

  Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

  Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the addition of omalizumab, referencing XOLAIR ® , to its biosimilar pipeline.

  July 1, 2024

   · 

  7 min read
• Press Releases

  KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Oncolytic Immunotherapy VET3-TGI for Solid Tumors

  KaliVir Immunotherapeutics, Inc. today announced that the FDA has cleared the Investigational New Drug (IND) application for the STEALTH-001 study of VET3-TGI in patients with incurable, advanced solid tumors.

  July 1, 2024

   · 

  2 min read
• Press Releases

  Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)

  Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has entered into an exclusive licensing agreement for ADL018 with Amneal Pharmaceuticals, Inc.

  July 1, 2024

   · 

  7 min read
• BioMidwest

  DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement

  DiaMedica Therapeutics Inc. today announced the closing of its previously announced $11.8 million private placement to accredited investors.

  July 1, 2024

   · 

  9 min read
• BioMidwest

  Anbio Biotechnology to Showcase at ADLM 2024 with Evolved In Vitro Diagnostic Solutions

  Anbio Biotechnology (“Anbio”), a leading global diagnostic solution provider, is excited to announce its participation in the ADLM 2024 Clinical Lab Expo (formerly the AACC Clinical Lab Expo).

  July 1, 2024

   · 

  1 min read
• Biotech Beach

  GRI Bio to Present at the 8th Annual IPF Summit

  GRI Bio, Inc. today announced that Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio, will present at the 8th Annual IPF Summit taking place August 20-22, 2024 in Boston, MA.

  July 1, 2024

   · 

  4 min read
• Drug Development

  Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium

  Artelo Biosciences, Inc. today announced Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented preclinical data related to ART26.12.

  July 1, 2024

   · 

  5 min read
• Press Releases

  Radionetics Oncology Enters Into Strategic Agreement With Lilly

  Radionetics Oncology announced today the formation of a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals.

  July 1, 2024

   · 

  2 min read